New Vanderbilt research provides evidence that the addition of palliative care services earlier in the disease process, specifically to patients having surgery for cancer, does not demonstrate benefits to the patients.

Vanderbilt is launching a clinical trial that pairs an experimental vaccine with an established immunotherapy for recurrent, human papilloma virus (HPV)-related oropharyngeal cancer of the head and neck.

A Vanderbilt-led study evaluating two investigational drugs to treat severe COVID-19 demonstrated that neither drug was effective.

Algorithms to infer missing problems and suggest that they be added to electronic health records improved problem list completeness, with benefits for clinical care, patient comprehension of health conditions and population health.

More than 75% of patients facing amputation from the most severe form of peripheral artery disease were able to keep their limb after an innovative treatment as part of a multicenter study published in the New England Journal of Medicine.

A Vanderbilt study of a treatment to delay the development of Type 1 diabetes in individuals at high risk did not meet the study goals of delaying progression from normal glucose tolerance to abnormal glucose tolerance or clinical diagnosis, although the study drug, abatacept, impacted immune response and preserved insulin production during the one-year treatment period.

A Vanderbilt study found that automated targeted reminders for clinicians helped increase prescribing of high intensity statins for patients with various atherosclerotic cardiovascular disease diagnoses, including coronary or peripheral artery disease and ischemic stroke.